Related Experiment Videos

Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a

Jiunn-Horng Chen1, Shao-Yuan Chuang, Hsin-Jen Chen

  • 1China Medical University Hospital, Taichung, and National Taiwan University, Taipei, Taiwan.

Arthritis and Rheumatism
|January 30, 2009
PubMed

Insights

High serum uric acid levels, or hyperuricemia, increase the risk of death from all causes, cardiovascular disease, and stroke in the general Taiwanese population. This risk is present even in individuals with low metabolic risk factors.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Epidemiology

Background:

  • Hyperuricemia is linked to cardiovascular events in high-risk populations.
  • Its association with cardiovascular mortality in the general population, particularly in Chinese individuals, remains unclear.

Purpose of the Study:

  • To investigate the temporal relationship between serum uric acid levels, hyperuricemia, and cardiovascular mortality.
  • To assess hyperuricemia as an independent risk factor for mortality in a large Taiwanese cohort.

Main Methods:

  • A prospective cohort study involving 41,879 men and 48,514 women aged 35 years or older in Taiwan.
  • Serum uric acid levels were measured, and mortality from all causes, total cardiovascular disease (CVD), ischemic stroke, congestive heart failure, hypertensive disease, and coronary heart disease were analyzed.
  • Cox regression models were used to estimate hazard ratios (HRs) for hyperuricemia (>7 mg/dl), adjusting for multiple risk factors.

Main Results:

  • Over a mean follow-up of 8.2 years, 5,427 deaths occurred, with 1,151 (21.2%) attributed to CVD.
  • Hyperuricemia was associated with increased all-cause mortality (HR=1.16, P<0.001), total CVD mortality (HR=1.39, P<0.001), and ischemic stroke mortality (HR=1.35, P=0.02).
  • These associations remained significant in subgroups with hypertension and diabetes, and showed a trend in the low metabolic risk subgroup.

Conclusions:

  • Hyperuricemia is an independent risk factor for all-cause mortality, total cardiovascular disease, and ischemic stroke in the Taiwanese general population.
  • The findings extend to high-risk groups and suggest potential risk in low-risk individuals.
  • Elevated serum uric acid levels warrant attention for cardiovascular risk assessment across diverse populations.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...